Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.77 CAD
Change Today +0.01 / 1.32%
Volume 500.0
IGX On Other Exchanges
As of 9:30 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

intelgenx technologies corp (IGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/15 - C$1.15
52 Week Low
11/5/14 - C$0.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

intelgenx technologies corp (IGX) Related Businessweek News

No Related Businessweek News Found

intelgenx technologies corp (IGX) Details

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0010/2006 for cancer pain; INT0024/2010 for idiopathic pulmonary fibrosis; INT0027/2011 for opioid dependence; INT0030/2011 for animal health; and INT0036/2012 for central nervous system disorders, as well as INT0037/2013, INT0039/2013, and INT0040/2013. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology; and a strategic manufacturing partnership with Pillar5 Pharma Inc. It also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada.

12 Employees
Last Reported Date: 03/31/15
Founded in 2003

intelgenx technologies corp (IGX) Top Compensated Officers

Founder, Chairman of the Board, Chief Executi...
Total Annual Compensation: $142.1K
Compensation as of Fiscal Year 2014.

intelgenx technologies corp (IGX) Key Developments

IntelGenx Corp. Announces Earnings Results for the First Quarter Ended March 31, 2015

IntelGenx Corp. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported cash used in operating activities of $279,000 against $588,000 in 2014. Revenue for the three months ended March 31, 2015 increased almost threefold to $625,000, compared with $222,000 for the first three months of 2014. Revenue recorded in the first quarter of 2015 relates exclusively to Forfivo XL, the first FDA approved product launched in October 2012 under a licensing partnership with Edgemont, and includes $391,000 of license revenue against $125,000 a year ago and $234,000 royalty income of $97,000 a year ago. IntelGenx generated an operating profit of $15,000 during the first three months of 2015, compared with an operating loss of $442,000 during the first three months of 2014. The net loss decreased from $442,000 during the first three months of 2014 to a loss of $54,000 during the first three months of 2015, and the loss per share was $0.00 for the first three months of 2015, compared with a loss per share of $0.01 for the first three months of 2014.

IntelGenx Technologies Corp. Announces Retirement Paul Simmons as Chief Financial Officer, Effective May 22, 2015

IntelGenx Technologies Corp. announced that Mr. Paul Simmons has resigned as chief financial officer of IntelGenx Technologies Corp. and IntelGenx Corp, effective May 22, 2015.

IntelGenx Technologies Corp. to Report Q1, 2015 Results on May 14, 2015

IntelGenx Technologies Corp. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 14, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IGX:CN C$0.77 CAD +0.01

IGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $8.15 USD +0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation IGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.1x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELGENX TECHNOLOGIES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at